MONECO Advisors LLC Has $512,000 Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

MONECO Advisors LLC raised its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 12.3% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 6,317 shares of the biopharmaceutical company’s stock after purchasing an additional 691 shares during the period. MONECO Advisors LLC’s holdings in Gilead Sciences were worth $512,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in GILD. Tompkins Financial Corp boosted its stake in Gilead Sciences by 223.1% during the 3rd quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 241 shares during the last quarter. Fortitude Family Office LLC acquired a new position in Gilead Sciences during the 4th quarter valued at about $29,000. Private Wealth Management Group LLC acquired a new position in Gilead Sciences during the 4th quarter valued at about $29,000. Sachetta LLC acquired a new position in Gilead Sciences during the 4th quarter valued at about $30,000. Finally, Rakuten Securities Inc. bought a new position in shares of Gilead Sciences during the 4th quarter worth approximately $33,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have commented on the stock. HSBC raised shares of Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 target price on the stock in a research report on Wednesday, April 24th. Royal Bank of Canada reissued a “sector perform” rating and set a $74.00 target price on shares of Gilead Sciences in a research report on Friday. Maxim Group dropped their target price on shares of Gilead Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a research report on Wednesday, May 1st. Barclays dropped their target price on shares of Gilead Sciences from $80.00 to $76.00 and set an “equal weight” rating on the stock in a research report on Monday, April 29th. Finally, StockNews.com raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research report on Saturday, April 27th. Eleven analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $83.69.

Gilead Sciences Trading Down 1.2 %

NASDAQ:GILD opened at $64.27 on Tuesday. The firm’s 50 day moving average is $65.92 and its 200 day moving average is $73.23. The company has a current ratio of 1.08, a quick ratio of 0.94 and a debt-to-equity ratio of 1.31. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $87.86. The stock has a market capitalization of $80.07 billion, a PE ratio of 178.53, a price-to-earnings-growth ratio of 1.30 and a beta of 0.20.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.49) by $0.17. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The business had revenue of $6.69 billion for the quarter, compared to analysts’ expectations of $6.36 billion. During the same quarter in the previous year, the firm posted $1.37 EPS. The business’s revenue for the quarter was up 5.3% compared to the same quarter last year. Sell-side analysts expect that Gilead Sciences, Inc. will post 3.75 earnings per share for the current year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 27th. Shareholders of record on Friday, June 14th will be issued a dividend of $0.77 per share. The ex-dividend date of this dividend is Friday, June 14th. This represents a $3.08 dividend on an annualized basis and a yield of 4.79%. Gilead Sciences’s payout ratio is 855.56%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $72.96, for a total transaction of $145,920.00. Following the sale, the insider now owns 96,304 shares of the company’s stock, valued at approximately $7,026,339.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.29% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.